CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Background Adoptive transfer of tumor-infiltrating lymphocytes (TIL) is now a Food and Drug Administration (FDA)-approved treatment for melanoma. While this is a major milestone, there is room for improvement to increase clinical response rates and to further optimize the manufacturing of TIL produc...

Full description

Saved in:
Bibliographic Details
Main Authors: Chao Wang, Shari Pilon-Thomas, Daniel Abate-Daga, Anders Berglund, Amod Sarnaik, Dongliang Du, James J Mulé, Leticia Tordesillas, Yian Ann Chen, Sebastian Snedal, Junior Cianne, Benjamin Creelan, Renata Ariza Marques Rossetti, Matthew S Beatty, Elena Martinez Planes, Bradford A Perez
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/4/e011066.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/4/e011066.full

Similar Items